A Phase 4 interventional study of etoricoxib in Pain, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing etoricoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Etoricoxib · Pain.
Among the 14 studies testing etoricoxib in Pain, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 9 in phase 4, and was the 5th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 14 studies testing etoricoxib in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 9
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 75 across the 14 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 6 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing etoricoxib in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect disease burden of OA and the effectiveness and patient satisfaction of treatment by Etoricoxib in the normal practice setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Etoricoxib
Drug: etoricoxib
etoricoxib 60 mg QD for 4 weeks.
Also known as: Arcoxia
The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4
WOMAC for pain assessment by patient (0-100 mm Visual Analog Scale (VAS) with 0 represent "no pain" and 100 represent "extreme pain")
Time frame: Baseline and end of week 4
Mean Change From Baseline in Patient WOMAC Domain Scores at Week 4
The change from baseline in 3 domain scores (pain, stiffness, and difficult in doing daily activity) of WOMAC at week 4 were measured. Each domain comprises of questions and VAS scales for scoring. For pain domain, 0 represents no pain and 100 represents extreme pain; for stiffness domain, 0 represents no stiffness and 100 represents extreme stiffness; for difficult in doing daily activity domain, 0 represents no difficulty and 100 represents most difficulty.
Time frame: Baseline and Week 4
Physicians' Global Assessment of Patients' Response to Therapy at Baseline Using IGART (Investigator Global Assessment of Response to Therapy)
The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants who met the criteria of any of the 5 categories at baseline were collected.
Time frame: Baseline
Physicians' Global Assessment of Patients' Response to Therapy at Week 4 Using IGART
The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants met the criteria of any of the 5 categories at week 4 were collected.
Time frame: Week 4
Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Baseline
The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[Not present, moderate and extreme\] for discomfort and anxiety/depression.
Time frame: Baseline
Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Week 4
The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[ Not present, moderate and extreme\]for discomfort and anxiety/depression
Time frame: Week 4
Change From Baseline of Patient BPI (Brief Pain Inventory) Scores at Week 4
BPI consists of pain and pain interference domains. For pain (0=no pain to 10=extreme pain); for pain interference ( 0=no interference to 10= greatest interference).
Time frame: Baseline and Week 4
Changes From Baseline in Patient TSQM (Treatment Satisfaction Questionnaire for Medication) Domain Scores at Week 4
TSQM consists of four domains (effectiveness; side effect; convenience and overall satisfaction), domain scores ranged from 0 (0=worst) to 100 (100=best) were derived from converting the original Likert's scales to VAS scale.
Time frame: Baseline and Week 4
Change From Baseline in Number of Days Patient Miss From Work or House Keeping Work at Week 4
Time frame: Baseline and Week 4
Change From Baseline in Patient-SF36 (Short Form 36) Domain Scores at Week 4
Weighted scores of the 8 domains of SF36 (i.e., physical functioning; role limiting due to physical problem; bodily pain; general health; vitality; social functioning; role limiting due to emotional problem; mental health) were scored on a scale from 0 \~100, with 100 representing the best possible functioning)
Time frame: Baseline and Week 4
| Milestone | Etoricoxib |
|---|---|
| Started | 500 |
| Completed | 419 |
| Not completed | 81 |
| Withdrew: Adverse event | 15 |
| Withdrew: Lack of efficacy | 10 |
| Withdrew: Lost to follow-up | 28 |
| Withdrew: Withdrawal by subject | 27 |
| Withdrew: Other | 1 |
The change from baseline in 3 domain scores (pain, stiffness, and difficult in doing daily activity) of WOMAC at week 4 were measured. Each domain comprises of questions and VAS scales for scoring. For pain domain, 0 represents no pain and 100 represents extreme pain; for stiffness domain, 0 represents no stiffness and 100 represents extreme stiffness; for difficult in doing daily activity domain, 0 represents no difficulty and 100 represents most difficulty.
| Units on a Scale | Etoricoxib |
|---|---|
| WOMAC Pain subscale (n=418) | -10.0 ± 20.5 |
| WOMAC Stiffness subscale (n=418) | -7.9 ± 25.7 |
| WOMAC Physical Function subscale (n=416) | -8.0 ± 19.6 |
The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants who met the criteria of any of the 5 categories at baseline were collected.
| Percentage of Participants | Etoricoxib (Baseline) |
|---|---|
| No Response | 4.40 |
| Poor Response | 57.60 |
| Fair Response | 36.40 |
| Good Response | 1.60 |
| Excellent Response | 0.00 |
The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants met the criteria of any of the 5 categories at week 4 were collected.
| Percentage of Participants | Etoricoxib (Week 4) |
|---|---|
| No response | 5.81 |
| Poor response | 16.05 |
| Fair response | 35.35 |
| Good response | 36.74 |
| Excellent response | 6.05 |
WOMAC for pain assessment by patient (0-100 mm Visual Analog Scale (VAS) with 0 represent "no pain" and 100 represent "extreme pain")
| Percentage of Participants | Etoricoxib |
|---|---|
| The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4 | 52.04 |
The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[Not present, moderate and extreme\] for discomfort and anxiety/depression.
| Percentage of Participants | Baseline - EQ-5D |
|---|---|
| Motility (n=499) No problem | 54.91 |
| Motility (n=499) Some problem | 45.09 |
| Motility (n=499) Not able to carry out | 0.00 |
| Self care (n=499) No problem | 86.97 |
| Self care (n=499) Some problem | 12.63 |
| Self care (n=499) Not able to carry out | 0.40 |
| Daily activity (n=499) No problem | 54.91 |
| Daily activity (n=499) Some problem | 43.69 |
| Daily activity (n=499) Not able to carry out | 1.40 |
| Pain/Discomfort (n=500) Not present | 10.00 |
| Pain/Discomfort (n=500) Moderate | 79.60 |
| Pain/Discomfort (n=500) Extreme | 10.40 |
| Anxiety/Depressed (n=500) Not present | 51.60 |
| Anxiety/Depressed (n=500) Moderate | 44.00 |
| Anxiety/Depressed (n=500) Extreme | 4.40 |
The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[ Not present, moderate and extreme\]for discomfort and anxiety/depression
| Percentage of participants | Week 4 - EQ-5D |
|---|---|
| Motility (n=423) No problem | 67.61 |
| Motility (n=423) Some problem | 32.39 |
| Motility (n=423) Not able to carry out | 0.00 |
| Self care (n=422) No problem | 90.05 |
| Self care (n=422) Some problem | 9.48 |
| Self care (n=422) Not able to carry out | 0.47 |
| Daily activity (n=421) No problem | 61.76 |
| Daily activity (n=421) Some problem | 37.29 |
| Daily activity (n=421) Not able to carry out | 0.95 |
| Pain/Discomfort (n=421) Not present | 23.04 |
| Pain/Discomfort (n=421) Moderate | 73.63 |
| Pain/Discomfort (n=421) Extreme | 3.33 |
| Anxiety/Depressed (n=422) Not present | 61.37 |
| Anxiety/Depressed (n=422) Moderate | 36.97 |
| Anxiety/Depressed (n=422) Extreme | 1.66 |
BPI consists of pain and pain interference domains. For pain (0=no pain to 10=extreme pain); for pain interference ( 0=no interference to 10= greatest interference).
| Units on a Scale | Etoricoxib |
|---|---|
| BPI Worst pain (n=418) | -1.5 ± 2.4 |
| BPI Least pain (n=417) | -0.6 ± 2.2 |
| BPI Average pain (n=419) | -1.0 ± 2.0 |
| BPI Pain right now (n=416) | -1.3 ± 2.6 |
| BPI Interference on general activities (n=419) | -0.8 ± 2.5 |
| BPI Interference on Mood (n=419) | -1.0 ± 2.7 |
| BPI Interference on Walking (n=419) | -1.2 ± 2.5 |
| BPI Interference on Normal work (n=419) | -1.1 ± 2.8 |
| BPI Interference on Relations (n=418) | -0.6 ± 2.6 |
| BPI Interference on Sleep (n=419) | -1.0 ± 2.8 |
| BPI Interference on Enjoyment of life(n=419) | -0.8 ± 2.7 |
TSQM consists of four domains (effectiveness; side effect; convenience and overall satisfaction), domain scores ranged from 0 (0=worst) to 100 (100=best) were derived from converting the original Likert's scales to VAS scale.
| Units on a Scale | Etoricoxib |
|---|---|
| Effectiveness ((n=418) | 2.8 ± 17.0 |
| Side Effect (n=22) | -3.8 ± 16.4 |
| Convenience (n=418) | 0.9 ± 10.8 |
| Overall (n=419) | 1.1 ± 20.9 |
| Days | Etoricoxib |
|---|---|
| Days Missed From Work (n=138) | -0.4 ± 1.6 |
| Days Missed From Housekeeping Work (n=411) | -2.3 ± 6.8 |
Weighted scores of the 8 domains of SF36 (i.e., physical functioning; role limiting due to physical problem; bodily pain; general health; vitality; social functioning; role limiting due to emotional problem; mental health) were scored on a scale from 0 \~100, with 100 representing the best possible functioning)
| Units on a Scale | Etoricoxib 60 mg q.d. |
|---|---|
| SF36 Physical Functioning (n=418) | 5.2 ± 19.9 |
| SF36 Role Limiting Due to Physical Problem (n=418) | 17.6 ± 49.3 |
| SF36 Bodily Pain (n=418) | 10.6 ± 17.7 |
| SF36 General Health (n=419) | 2.0 ± 16.2 |
| SF36 Vitality (n=417) | 1.4 ± 15.1 |
| SF36 Social Functioning (n=419) | 8.7 ± 20.3 |
| SF36 Role Limiting Due to Emotional Problem(n=418) | 14.0 ± 50.4 |
| SF36 Mental Health (n=417) | 4.4 ± 14.0 |
Collected over From baseline to end of week 4. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etoricoxib | — | 6/500 (1.2%) | 82/500 (16.4%) |
| Event | Etoricoxib |
|---|---|
| Peritoneal adhesionGastrointestinal disorders | 1/500 |
| Bacterial infectionInfections and infestations | 1/500 |
| Lung abscess, chest pain/tightness and tremorGeneral disorders | 1/500 |
| Traffic accidentInjury, poisoning and procedural complications | 1/500 |
| UrethritisRenal and urinary disorders | 1/500 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/500 |
| Event | Etoricoxib |
|---|---|
| Edema , face/eye /hand/legVascular disorders | 24/500 |
| DizzinessNervous system disorders | 11/500 |
| Hypertension / elevated blood pressureVascular disorders | 9/500 |
| PalpitationCardiac disorders | 8/500 |
| Skin rashSkin and subcutaneous tissue disorders | 7/500 |
| Abdominal distension / flatulenceGastrointestinal disorders | 6/500 |
| Abdominal pain, upperGastrointestinal disorders | 6/500 |
| NauseaGastrointestinal disorders | 6/500 |
| HeadacheNervous system disorders | 5/500 |
| Age, Continuous(years) | Etoricoxib |
|---|---|
| Mean | 66.6 ± 10.9 |
| Sex: Female, Male(Participants) | Etoricoxib |
|---|---|
| Female | 365 |
| Male | 135 |
| Patient-SF36 (Short form 36) domain scores(Units on a scale) | Etoricoxib |
|---|---|
| SF-36 Physical functional | 45.1 ± 51.3 |
| SF-36 Role limitation due to physical problem | 24.0 ± 42.5 |
| SF-36 Bodily pain | 52.4 ± 63.9 |
| SF-36 General health | 52.7 ± 54.5 |
| SF-36 Vitality | 55.9 ± 57.6 |
| SF-36 Social functioning | 69.0 ± 78.3 |
| SF-36 Role limitation due to emotional problem | 41.3 ± 56.6 |
| SF-36 Mental health | 61.7 ± 66.3 |
| TSQM (Treatment Satisfaction Questionnaire for Medication )domain scores(Units on a scale) | Etoricoxib |
|---|---|
| TSQM - Effectiveness | 52.1 ± 55.6 |
| TSQM - Side effect | 56.9 ± 55.7 |
| TSQM - Convenience | 68.0 ± 68.8 |
| TSQM - Overall satisfaction | 44.1 ± 45.7 |
| The mean of patient BPI (Brief Pain Inventory) scores(Units on a scale) | Etoricoxib |
|---|---|
| BPI -Worst pain | 6.4 ± 4.9 |
| BPI -Least pain | 3.2 ± 2.5 |
| BPI-Average pain | 4.9 ± 3.8 |
| BPI -Pain right now | 4.4 ± 3.1 |
| BPI -Interference on general activities | 2.9 ± 2.1 |
| BPI - Mood | 3.2 ± 2.2 |
| BPI -Walking | 4.3 ± 2.9 |
| BPI - Normal work | 4.2 ± 2.9 |
| BPI- Relations with other people | 2.5 ± 1.9 |
| BPI - Sleep | 3.3 ± 2.3 |
| BPI - Enjoyment of life | 3.0 ± 2.1 |
| The mean of patient WOMAC ( Western Ontario and McMaster Universities Osteoarthritis Index) subscale(Units on a Scale) | Etoricoxib |
|---|---|
| WOMAC Pain subscale | 38.5 ± 22.9 |
| WOMAC Stiffness subscale | 36.3 ± 26.9 |
| WOMAC Physical Function subscale | 38.0 ± 24.8 |
No study locations are listed for this record.
The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib